EU Medicines Agency @EMA_News@respublicae.eu

RT by @EMA_News: 1⃣ week to go!

Have you registered for our event to mark #WorldCancerDay yet?
If not, do it fast because today is the last day for in person registration. And if you can’t make it to Brussels, you can follow here on our @EU_Health X account.

#EUCancerPlan #HealthUnion

🐦🔗: https://nitter.cz/EU_Health/status/1750071471953567834#m

[2024-01-24 08:22 UTC]

RT by @EMA_News: Let's fight #CervicalCancer together & save 15 000 lives each year!

Watch our animation about the vaccine protecting from #HPV infection - the main cause of cervical cancer & share it with friends!

Info: https://bit.ly/3u5OMC9

#UnitedInProtection #CervicalCancerAwarenessMonth

🐦🔗: https://nitter.cz/ECDC_EU/status/1749816138165612868#m

[2024-01-23 15:27 UTC]

RT by @EMA_News: Upcoming event: @EMA_News Webinar on Rare World Diseases Day 29th February-Orphan medicines development - ask the European regulator. More info and registration: https://erica-rd.eu/event/ema-webinar-on-rare-world-diseases-day/

🐦🔗: https://nitter.cz/ERICA_RD_EU/status/1749793517470384223#m

[2024-01-23 13:57 UTC]

https://nitter.cz/search?q=%23JustPublished
!
EMA's updated
https://nitter.cz/search?q=%23SME
User Guide helps small & medium sized enterprises navigate the requirements for the development and authorisation of human and veterinary medicines.
Explore our guide and contact the SME Office for assistance.
👉
https://www.ema.europa.eu/en/news/major-update-sme-user-guide

🐦🔗: https://nitter.cz/EMA_News/status/1749802001968582816#m

[2024-01-23 14:31 UTC]

The agenda of EMA's human
https://nitter.cz/search?q=%23medicines
committee
https://nitter.cz/search?q=%23CHMP
is now published. 💊💉
Find out what medicines will be discussed this month:
https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-meeting-22-25-january-2024_en.pdf
The committee highlights will be released on Friday.

🐦🔗: https://nitter.cz/EMA_News/status/1749422543142822083#m

[2024-01-22 13:23 UTC]

RT by @EMA_News: Join us for a Conversation on Cancer Feb. 1 for World Cancer Day with @EMA_News. The panel of patients, investigators & regulators will discuss new therapies revolutionizing care for patients with chronic myeloid leukemia, multiple myeloma & melanoma. https://www.surveymonkey.com/r/HDNCD2Y

🐦🔗: https://nitter.cz/FDAOncology/status/1747967134162887005#m

[2024-01-18 13:00 UTC]

‼️ EMA will hold its first press briefing of 2024, where we will be discussing key developments in human
https://nitter.cz/search?q=%23medicines
throughout 2023.
It will be broadcast live 🔴 today, 16 Jan, from 14:30 to 15:00 CET.
https://nitter.cz/search?q=%23EMAPresser
👉
https://www.ema.europa.eu/en/events/ema-press-briefing-human-medicines-highlights-2023

🐦🔗: https://nitter.cz/EMA_News/status/1747243954062451128#m

[2024-01-16 13:06 UTC]

R to @EMA_News: We will start the press briefing at 14h30 CET

🐦🔗: https://nitter.cz/EMA_News/status/1747247687441731771#m

[2024-01-16 13:21 UTC]

R to @EMA_News: Watch live 🔴

We are now starting our press briefing on medicines that were approved last year and trends we are observing in human medicines.

Don’t miss our tweets 🧵 during the press briefing. Follow #EMAPresser

🐦🔗: https://nitter.cz/EMA_News/status/1747250220000289243#m

[2024-01-16 13:31 UTC]

R to @EMA_News: We published an overview of human medicines highlights this morning ⬇️

#EMAPresser

https://x.com/EMA_News/status/1747204037701669370?s=20

🐦🔗: https://nitter.cz/EMA_News/status/1747250732598751700#m

[2024-01-16 13:33 UTC]

R to @EMA_News: Therapeutic areas with the highest numbers of new approval recommendations:
1⃣ oncology,
2⃣ neurology,
3⃣ cardiovascular.

#EMAPresser

🐦🔗: https://nitter.cz/EMA_News/status/1747251070345077176#m

[2024-01-16 13:34 UTC]

R to @EMA_News: Outstanding medicines:
🔶1st product using new gene-editing technology #CRISPR/Cas9 to treat rare blood disorders
🔶2 vaccines against #RSV
🔶new medicines for children, one to treat heart failure and the other to prevent hearing loss or balance problems in chemotherapy patients.

🐦🔗: https://nitter.cz/EMA_News/status/1747251714670158120#m

[2024-01-16 13:37 UTC]

R to @EMA_News: Half of our positive recommendations on new therapeutic indications for existing medicines were for treatment of children 👦👧

This figure is considerably higher than in previous years.

#EMAPresser #MedicinesForChildren

🐦🔗: https://nitter.cz/EMA_News/status/1747252124348723345#m

[2024-01-16 13:39 UTC]

R to @EMA_News: We provided 2 recommendations for use of medicines outside the 🇪🇺 (#EUM4All):
🔶 a new treatment option for 50 million children with a tropical disease caused by parasites
🔶a medicine to treat an acute and lethal form of sleeping sickness

@WHO #EMAPresser #GlobalHealth

🐦🔗: https://nitter.cz/EMA_News/status/1747252409414602791#m

[2024-01-16 13:40 UTC]

R to @EMA_News: In 2023, we approved 8 #biosimilars for a wide range of diseases, including a rare genetic disease, #cancers, #multiplesclerosis.

The total of 9⃣7⃣ biosimilars that can be marketed in 🇪🇺 make treatments more accessible and can improve the quality of life for more #patients.

🐦🔗: https://nitter.cz/EMA_News/status/1747252697924006358#m

[2024-01-16 13:41 UTC]

R to @EMA_News: Last year, we also continued our work to tackle #COVID19, in particular with the evaluation of a new vaccine and 3 updated vaccines. 💉

#EMAPresser #COVID19Vaccines

🐦🔗: https://nitter.cz/EMA_News/status/1747253014438838691#m

[2024-01-16 13:42 UTC]

R to @EMA_News: We are committed to progressing treatments against #cancer and to supporting Europe’s beating cancer plan.

Cancer is an area of high unmet medical need and a major health concern in the 🇪🇺.

#EMAPresser #EUCancerPlan #HealthUnion

🐦🔗: https://nitter.cz/EMA_News/status/1747253264356405351#m

[2024-01-16 13:43 UTC]

R to @EMA_News: A third of all new medicines with a positive opinion in 2023 targeted cancer , i.e. 2⃣5⃣ new cancer medicines were recommended for approval last year.

#EMAPresser

🐦🔗: https://nitter.cz/EMA_News/status/1747253496460784019#m

[2024-01-16 13:44 UTC]

R to @EMA_News: To support development and earlier assessment of medicines that address unmet medical needs for #cancer patients
➡️ 7 were reviewed in view of a conditional marketing authorisation
➡️ 1 had accelerated assessment
➡️ 2 were part of the #PRIME scheme

#EMAPresser

🐦🔗: https://nitter.cz/EMA_News/status/1747253499493261624#m

[2024-01-16 13:44 UTC]

R to @EMA_News: #Cancer is an area where top innovation and scientific progress happen quickly. That’s why EMA decided to use this therapeutic area as a pathfinder to improve medicines evaluation overall. #EMAPresser

🐦🔗: https://nitter.cz/EMA_News/status/1747253899109822673#m

[2024-01-16 13:46 UTC]